This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

5 Stocks Pushing The Drugs Industry Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 40 points (0.3%) at 12,582 as of Friday, Nov. 16, 2012, 11:59 AM ET. The NYSE advances/declines ratio sits at 1,549 issues advancing vs. 1,392 declining with 99 unchanged.

The Drugs industry currently sits down 0.7% versus the S&P 500, which is down 0.1%. A company within the industry that fell today was Eli Lilly and Company ( LLY), up 0.9%. Top gainers within the industry include Regeneron Pharmaceuticals ( REGN), up 7.8%, Gilead ( GILD), up 1.5% and Bristol-Myers Squibb Company ( BMY), up 1.6%.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry lower today:

5. Dynavax Technologies Corporation ( DVAX) is one of the companies pushing the Drugs industry lower today. As of noon trading, Dynavax Technologies Corporation is down $2.27 (-49.0%) to $2.36 on heavy volume Thus far, 23.3 million shares of Dynavax Technologies Corporation exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $2.22-$2.51 after having opened the day at $2.30 as compared to the previous trading day's close of $4.63.

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. Dynavax Technologies Corporation has a market cap of $827.4 million and is part of the health care sector. The company has a P/E ratio of -14.5, below the S&P 500 P/E ratio of 17.7. Shares are up 39.5% year to date as of the close of trading on Thursday. Currently there are 4 analysts that rate Dynavax Technologies Corporation a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Dynavax Technologies Corporation as a sell. Among the areas we feel are negative, one of the most important has been unimpressive growth in net income over time. Get the full Dynavax Technologies Corporation Ratings Report now.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
Submit an article to us!
DOW 16,614.81 +215.14 1.31%
S&P 500 1,941.28 +37.27 1.96%
NASDAQ 4,419.4780 +103.4040 2.40%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs